Brief: Erytech Updates On Phase 2 Eryaspase Trial In Acute Lymphoblastic Leukemia

Phaxiam Therapeutics SA

09/06/2020 06:39

June 9 (Reuters) - ERYTECH PHARMA SA  ERYP.PA :
    * PROVIDES UPDATE ON PHASE 2 INVESTIGATOR SPONSORED TRIAL OF
ERYASPASE IN SECOND-LINE ACUTE LYMPHOBLASTIC LEUKEMIA
    * ENCOURAGING PRELIMINARY RESULTS BASED ON INTERIM DATA
    * PRELIMINARY FINDINGS OF STUDY SUGGEST THAT ERYASPASE
ACHIEVED
TARGET LEVEL AND DURATION OF ASPARAGINASE ACTIVITY IN THESE
PATIENTS
    * UNMET MEDICAL NEED CONFIRMED BY FDA
    * PATIENT ENROLLMENT COMPLETED; 50 PATIENTS IN TRIAL

Source text for Eikon:  ID:nGNE7fTg81 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))